Evaluating Type 2 Meds, Part 5: SGLT-2 (Sodium-Glucose Co-Transporter 2) Inhibitors

SGLT-2 Inhibitors including Invokana (canagliflozin), Farxiga (dapagliflozin), Jardiance (empagliflozin) and Steglatro (ertugliflizin), are the newest class of oral medications for the treatment of type 2 diabetes. They’re generally well tolerated and associated with significant weight loss compared with other type 2 oral meds, but there are still precautions to consider.

read more